Beta2-adrenergic receptor agonists
AssigneeTheravance, Inc.
InventorsEdmund J. Moran, John H. Griffin, Seok-Ki Choi
Life of this patent
Estimating the term…
Abstract
Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.
Claims49
A multibinding compound of Formula (I):
- (L)p(X)q (I)
- wherein:
- p is an integer of from 2 to 10;
- q is an integer of from 1 to 20;
- X is a linker;
- and
- L is a ligand wherein:
- one of the ligands, L, is selected from a compound of formula (a):
- 48
- wherein:
- Ar1 and Ar2 are independently selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl wherein each of said Ar1 and Ar2 substituent optionally links the ligand to a linker;
- R1 is selected from the group consisting of hydrogen, alkyl and substituted alkyl, or R1 is a covalent bond linking the ligand to a linker;
- R2 is selected from the group consisting of hydrogen, alkyl, aralkyl, acyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl, or R2 is a covalent bond linking the ligand to a linker;
- W is a covalent bond linking the —NR2— group to Ar2, alkylene or substituted alkylene wherein one or more of the carbon atoms in said alkylene or substituted alkylene group which is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and further wherein said alkylene or substituted alkylene group optionally links the ligand to a linker provided that at least one of Ar1, Ar2, R1, R2, or W links the ligand to a linker;
- and
- the other ligands are independently selected from a compound of formula (b):
- -Q-Ar3 (b)
- wherein:
- Ar3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl;
- Q, which links the other ligand to the linker, is selected from the group consisting of a covalent bond, alkylene or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—. —S(O)n— (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O— P(O)O—;
- and
- pharmaceutically acceptable salts thereof provided that:
- (i) when the multibinding compound of Formula (I) is a compound of formula:
- 49
- where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alkylene-O—:
- (ii) when the multibinding compound of Formula (I) is a compound of formula:
- 50
- where Ar1 is 4-hydroxy-2-methylphenyl, Ar2 is aryl, Ar3 is aryl or heterocyclyl, W is ethylene, Q is a covalent bond, R1 is alkyl then the linker X is not linked to the Ar3 group through an oxygen atom;
- and
- (iii) when the multibinding compound of Formula (I) is a compound of formula:
- 51
- where Ar1, Ar2, Ar3, R1, R2 are as defined above, W is alkylene, and Q is a covalent bond, then X is not -alkylene-O—.
The multibinding compound of claim 2 wherein q is less than p
A bivalent multibinding compound of Formula (II):
- 52
- wherein:
- Ar1 is:
- (a) a phenyl ring of formula (c):
- 53
- wherein:
- R4 is hydrogen, alkyl, halo, or alkoxy;
- R5 is hydrogen, hydroxy, halo, halo, amino, or —NHSO2Ra where Ra is alkyl;
- R6 is hydrogen, halo, hydroxy, alkoxy, substituted alkyl, sulfonylamino, aminoacyl, or acylamino;
- W is a bond linking the —NR2— group to Ar2, an alkylene or substituted alkylene chain wherein one or more of the carbon atoms in the alkylene or substituted alkylene group are optionally replaced by —O—;
- Ar2 is phenyl wherein the W and the X groups are attached at the 1,2-, 1,3, and 1,4 positions of the phenyl ring;
- cyclohexyl optionally substituted with methyl and wherein the W and the X groups are attached at the 1,3, and 1,4 positions of the cyclohexyl ring;
- or piperazine wherein the W and the X groups are attached at the 1,4 positions of the piperazine ring:
- X is a linker;
- Q is a covalent bond, alkylene, or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a heteroatom such as —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and links the ligand to a linker;
- and
- Ar3 is either:
- (i) a phenyl ring of formula (c) as defined above;
- or
- (ii) a phenyl ring of formula (d):
- 54
- wherein:
- R7 is hydrogen, alkyl, alkenyl, substituted alkyl, halo, alkoxy, substituted alkoxy, hydroxy, aminoacyl, or heteroaryl;
- and
- R8 is hydrogen, halo, alkoxy, substituted alkoxy, acylamino;
- or
- (iii) naphthyl, pyridyl, benzimidazol-1-yl, indolyl, 2-cyanoindolyl, carbazolyl, 4-methsyindanyl, 5-(CH3CO2CH2O—)-1,2,3,4-tetrahydronaphthyl, 1H-2-oxoindole, 2,3,4-trihydrothianaphthalene, or 4-oxo-2,3-dihydrothianapthalene;
- and
- pharmaceutically acceptable salts thereof provided that:
- when the multibinding compound of Formula (I) is a compound of formula:
- 55
- where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alklylene-O—.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a multibinding compound of Formula (I):
- (L)p(X)q (I)
- wherein:
- p is an integer of from 2 to 10;
- q is an integer of from 1 to 20;
- X is a linker;
- and
- L is a ligand wherein:
- one of the ligands, L, is selected from a compound of formula (a):
- 63
- wherein:
- Ar1 and Ar2 are independently selected from the group consisting of aryl, heteroaryl, cycloalkyl substituted cycloalkyl, and heterocyclyl wherein each of said Ar1 and Ar2 substituent optionally links the ligand to a linker;
- R1 is selected from the group consisting of hydrogen, alkyl and substituted alkyl, or R1 is a covalent bond linking the ligand to a linker;
- R2 is selected from the group consisting of hydrogen, alkyl, aralkyl, acyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl, or R2 is a covalent bond linking the ligand to a linker;
- W is a covalent bond linking the —NR2— group to Ar2, alkylene or substituted alkylene wherein one or more of the carbon atoms in said alkylene or substituted alkylene group which is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and further wherein said alkylene or substituted alkylene group optionally links the ligand to a linker provided that at least one of Ar1, Ar2, R1, R2, or W links the ligand to a linker;
- and
- the other ligands are independently selected from a compound of formula (b):
- -Q-Ar3 (b)
- wherein:
- Ar3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl;
- Q, which links the other ligand to the linker, is selected from the group consisting of a covalent bond, alkylene, or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n— (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O—;
- and
- pharmaceutically acceptable salts thereof provided that:
- (i) when the multibinding compound of Formula (I) is a compound of formula:
- 64
- where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alkylene-O—;
- (ii) when the multibinding compound of Formula (I) is a compound of formula:
- 65
- where Ar1 is 4-hydroxy-2-methylphenyl, Ar2 is aryl, Ar3 is aryl or heterocyclyl, W is ethylene, Q is a covalent bond, R1 is alkyl, then the linker X is not linked to the Ar3 group through an oxygen atom;
- and
- (iii) when the multibinding compound of Formula (I) is a compound of formula:
- 66
- where Ar1, Ar2, Ar3, R1, R2 are as defined above, W is alkylene, and Q is a covalent bond, then X is not -alkylene-O—.
A method for treating diseases mediated by a β2 adrenergic receptor in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a multibinding compound of Formula (I):
- (L)p(X)q
- wherein:
- p is an integer of from 2 to 10;
- q is an integer of from 1 to 20;
- X is a linker;
- and
- L is a ligand wherein:
- one of the ligands, L, is selected from a compound of formula (a):
- 67
- wherein:
- Ar1 and Ar2 are independently selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl wherein each of said Ar1 and Ar2 substituent optionally links the ligand to a linker;
- R1 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl, or R1 is a covalent bond linking the ligand to a linker;
- R2 is selected from the group consisting of hydrogen, alkyl, aralkyl, acyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl, or R2 is a covalent bond linking the ligand to a linker;
- W is a covalent bond linking the —NR2— group to Ar2, alkylene or substituted alkylene wherein one or more of the carbon atoms in said alkylene or substituted alkylene group which is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and further wherein said alkylene or substituted alkylene group optionally links the ligand to a linker provided that at least one of Ar1, Ar2, R1, R2, or W links the ligand to a linker;
- and
- the other ligands are independently selected from a compound of formula (b):
- -Q-Ar3 (b)
- wherein:
- Ar3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl;
- Q, which links the other ligand to the linker, is selected from the group consisting of a covalent bond, alkylene, or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n— (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O—;
- and
- pharmaceutically acceptable salts thereof provided that:
- (i) when the multibinding compound of Formula (I) is a compound of formula:
- 68
- where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alkylene-O—;
- (ii) when the multibinding compound of Formula (I) is a compound of formula:
- 69
- where Ar1 is 4-hydroxy-2-methylphenyl, Ar2 is aryl, Ar3 is aryl or heterocyclyl, W is ethylene, Q is a covalent bond, R1 is alkyl, then the linker X is not linked to the Ar3 group through an oxygen atom;
- and
- (iii) when the multibinding compound of Formula (I) is a compound of formula:
- 70
- where Ar1, Ar2, Ar3, R1, R2 are as defined above, W is alkylene, and Q is a covalent bond, then X is not -alkylene-O—.
A method for identifying multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor which method comprises:
- (a) identifying a ligand or a mixture of ligands wherein each ligand contains at least one reactive functionality;
- (b) identifying a library of linkers wherein each linker in said library comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand;
- (c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the ligand or mixture of ligands identified in (a) with the library of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands;
- and
- (d) assaying the multimeric ligand compounds produced in the library prepared in (c) above to identify multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor.
A method for identifying multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor which method comprises:
- (a) identifying a library of ligands wherein each ligand contains at least one reactive functionality;
- (b) identifying a linker or mixture of linkers wherein each linker comprises at least two functional groups having complementary reactivity to at least one of the reactive function al groups of the ligand;
- (c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the library of ligands identified in (a) with the linker or mixture of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands;
- and
- (d) assaying the multimeric ligand compounds produced in the library prepared in (c) above to identify multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor.
A library of multimeric ligand compounds which may possess multivalent properties for β2 adrenergic receptor which library is prepared by the method comprising
- (a) identifying a ligand or a mixture of ligands wherein each ligand contains at least one reactive functionality;
- (b) identifying a library of linkers wherein each linker in said library comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand;
- and
- (c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the ligand or mixture of ligands identified in (a) with the library of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands.
A library of multimeric ligand compounds which may possess multivalent properties for β2 adrenergic receptor which library is prepared by the method comprising:
- (a) identifying a library of ligands wherein each ligand contains at least one reactive functionality;
- (b) identifying a linker or mixture of linkers wherein each linker comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand;
- and
- (c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the library of ligands identified in (a) with the linker or mixture of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands.
An iterative method for identifying multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor which method comprises:
- (a) preparing a first collection or iteration of multimeric compounds which is prepared by contacting at least two stoichiometric equivalents of the ligand or mixture of ligands which target a receptor with a linker or mixture of linkers wherein said ligand or mixture of ligands comprises at least one reactive functionality and said linker or mixture of linkers comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand wherein said contacting is conducted under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands,
- (b) assaying said first collection or iteration of multimeric compounds to assess which if any of said multimeric compounds possess multibinding properties for β2 adrenergic receptor;
- (c) repeating the process of (a) and (b) above until at least one multimeric compound is found to possess multibinding properties for β2 adrenergic receptor;
- (d) evaluating what molecular constraints imparted multibinding properties to the multimeric compound or compounds found in the first iteration recited in (a)-(c) above;
- (e) creating a second collection or iteration of multimeric compounds which elaborates upon the particular molecular constraints imparting multibinding properties for β2 adrenergic receptor to the multimeric compound or compounds found in said first iteration;
- (f) evaluating what molecular constraints imparted enhanced multibinding properties to the multimeric compound or compounds found in the second collection or iteration recited in (e) above;
- (g) optionally repeating steps (e) and (f) to further elaborate upon said molecular constraints.
Dependencies are inferred from the claim text.